6838.TW Formosa Pharmaceuticals, Inc.
- Market cap
- TWD 3.17B
- P/E
- -
- P/B
- 2.31x
- ROE
- -12.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6838.TW undervalued?
Graham numberThe Graham number of Formosa Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Formosa Pharmaceuticals, Inc. fundamental analysis
No fundamental analysis for Formosa Pharmaceuticals, Inc. yet.
Formosa Pharmaceuticals, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- hist…
Full company profileFormosa Pharmaceuticals, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Formosa Pharmaceuticals, Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 28.5M | 1.32M | 31.2M | 143M | 9.50M | 96.9M |
| Gross Profit | 28.3M | 333K | 27.3M | 119M | -1.60M | 69.7M |
| Operating Income | -380M | -382M | -283M | -168M | -171M | -173M |
| EBITDA | - | -366M | -255M | -137M | -34.0M | -107M |
| Net Income | -401M | -406M | -322M | -201M | -83.6M | -166M |
| EPS | -3.91 | -3.47 | -2.40 | -1.33 | -0.55 | -1.10 |
| Balance Sheet | ||||||
| Total Assets | 689M | 878M | 1.73B | 2.11B | 2.07B | 1.93B |
| Total Liabilities | 295M | 411M | 586M | 564M | 614M | 554M |
| Shareholders' Equity | 393M | 467M | 1.14B | 1.55B | 1.46B | 1.37B |
| Cash & Short-term Investments | 209M | 267M | 385M | 426M | 242M | 107M |
| Cash Flow | ||||||
| Operating Cash Flow | -331M | -346M | -196M | -129M | -95.6M | -369M |
| Capital Expenditure | 15.1M | 0.00 | 2.25M | 8.25M | 41.9M | 76.7M |
| Free Cash Flow | -346M | -346M | -198M | -137M | -138M | -446M |
| Ratios | ||||||
| ROE | -102.1% | -87.0% | -28.2% | -13.0% | -5.7% | -12.1% |
| ROA | -58.2% | -46.3% | -18.6% | -9.5% | -4.0% | -8.6% |
| Net Profit Margin | -1,405.2% | -30,895.2% | -1,032.8% | -140.2% | -880.1% | -171.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Formosa Pharmaceuticals, Inc. dividends
Formosa Pharmaceuticals, Inc. has not paid dividends in the last 5 fiscal years.
Who owns Formosa Pharmaceuticals, Inc.
- Insiders 53.48%
- Institutions 0.94%
- Public & others 45.58%
- Shares outstanding 151M
- Free float 83.8M
Formosa Pharmaceuticals, Inc. company profile
- Company name
- Formosa Pharmaceuticals, Inc.
- Ticker
- 6838.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 57, Fuxing North Road, Taipei, Taiwan, 105
- Phone
- 886 2 2755 7659
- Website
- formosapharma.com
About Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer. It has a strategic partnership with Eyenovia, Inc. for the development of novel ophthalmic therapeutic; and Singapore Eye Research Institute to develop ophthalmic formulations for corneal diseases. Formosa Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Taipei City, Taiwan.
Formosa Pharmaceuticals, Inc. management
4- Dr. Erick Co Ph.D.President & CEO
- Mr. Nai Hsien TsaoDirector of Finance & Admn Div, Corp Governance Officer, CFO and Accounting Supervisor
- Mr. Ching Cheng Wei M.P.H.Chief Business & Strategy Officer
- Mr. Yu-Chi ChenDirector of Nanotechnology